

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/645,874
				Filing Date	August 20, 2003
				First Named Inventor	Kenneth F. Buechler
				Art Unit	1641
				Examiner Name	Ann Y. Lam
Sheet	1	of	5	Attorney Docket Number	36671-744.502

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US 2003/0236272 A1	12/25/2003	Carr	
	2.	US 2004/0203081 A1	10/14/2004	James et al.	
	3.	US 2004/0266673 A1	12/30/2004	Bakis et al.	
	4.	US 2008/0254485 A1	10/16/2008	Valkirs et al.	
	5.	US 2009/0061467 A1	03/05/2009	Buechler et al.	
	6.	US 2009/0275512 A1	11/05/2009	Whittaker	
	7.	US 7,427,490	08/20/2002	Valkirs	
	8.	US 7,553,937	06/30/2009	Pau et al.	
	9.	US 7,632,647	12/15/2009	Dahlen et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	10.	WO 2004/014952 A2 (in French with English abstract)	02/19/2004	Pau et al.		
	11.	WO 2004/014952 A3 (in French with English abstract)	04/08/2004	Pau et al.		
	12.	WO 2006/108686 A2	10/19/2006	Lambeir et al.		
	13.	WO 2006/108686 A3	10/19/2006	Lambeir et al.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/645,874
				Filing Date	August 20, 2003
				First Named Inventor	Kenneth F. Buechler
				Art Unit	1641
				Examiner Name	Ann Y. Lam
Sheet	2	of	5	Attorney Docket Number	36671-744.502

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	14.	ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. American College of Cardiology/American Heart Association. 2002; pages 1-3.	
	15.	ALPERT, et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000 Sep;36(3):959-69.	
	16.	Antman, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction : results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100:1593-1601.	
	17.	Antman, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835-842.	
	18.	BANAS, et al. Long-term management of patients with unstable angina and NSTEMI. J Fam Pract. 2004 Jun;53(6):451-5.	
	19.	Choy, et al. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart 11994;72:16-22.	
	20.	Cohen, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. NEJM. 1997;337:447-52.	
	21.	Copy of the executed assignment of the US Application No. 09/835,298 dated 07/09/2001.	
	22.	DARBAR et al. Diagnostic Value of B-Type Natriuretic Peptide Concentrations in Patients with Acute Myocardial Infarction. Am. J. Cardiology, 1996; 78:284-287.	
	23.	DE LEMOS et al. The Prognostic Value of B-Type natriuretic Peptide In Patients with Acute Coronary Syndromes. N. Engl. J. Med. 2001 Oct 4; 345(14):1014-1021.	
	24.	DE LEMOS, et al. Natriuretic peptides in the prognosis and management of acute coronary syndromes. Rev Cardiovasc Med. 2010;11 Suppl 2:S24-34.	
	25.	Decision dated 01/25/2011 for opposition against EP1311701.	
	26.	Declaration of Dr. Frank Peacock dated 11/24/2010.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/645,874
				Filing Date	August 20, 2003
				First Named Inventor	Kenneth F. Buechler
				Art Unit	1641
				Examiner Name	Ann Y. Lam
Sheet	3	of	5	Attorney Docket Number	36671-744.502

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	27.	Excerpt "roche Lexikon Medizin," 4th ed. 1998, page 822.	
	28.	Hamm, et al. Acute coronary syndrome without ST elevation: omplementation of new guidelines. Lancet 2001;358:1533-38.	
	29.	HINO, et al. Isolation and identification of human brain natriuretic peptides in cardiac atrium. Biochem Biophys Res Commun. 1990 Mar 16;167(2):693-700.	
	30.	HUGHES, et al. An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction. Clin Sci (Lond). 1999 Apr;96(4):373-80.	
	31.	Jabor, et al. Natriuretic peptides can predict cardiac failure. Klin. Biochem. Metab. 1999; 7(28):No1:44-48, abstract.	
	32.	JANEWAY, et al. ed. Immunobiology, 6th Ed, 2005. Publisher Garland Science. 2005; 112-113.	
	33.	KIKUTA at al. Increased Plasma Levels of B-Type Natriuretic Peptide In Patients with Unstable Angina. American Heart Journal, 1996; 132:1:101-107.	
	34.	LANG, et al. Dietary sodium loading increases plasma brain natriuretic peptide levels in man. J Hypertens. 1991 Sep;9(9):779-82.	
	35.	LIANG, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol. 2007 Mar 13;49(10):1071-8.	
	36.	MCDONAGH et al., Biochemical Detection of Left-Ventricular' Systolic Dysfunction, The Lancet, January 3, 1998, p. 9-13, Vol. 351.	
	37.	McDonagh, et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001;86:21-26.	
	38.	Notice Cobas® proBNP II. (Roche. 2008.06)	
	39.	OMLAND et al. N-terminal Pro-B-Type natriuretic peptide and long-term mortality in acute coronary syndrome. Circulation. 2002; 106:2913-18.	
	40.	OMLAND et al. Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term Survival After Acute Myocardial Infarction, Circulation, 1996 June 1; 93:11:1963-69.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/645,874
				Filing Date	August 20, 2003
				First Named Inventor	Kenneth F. Buechler
				Art Unit	1641
				Examiner Name	Ann Y. Lam
Sheet	4	of	5	Attorney Docket Number	36671-744.502

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	41.	Omland, et al. Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-129) and clinical evaluation. Br Heart J 1993;70:409-414.	
	42.	PATEL, et al. Early continuous ST segment monitoring in unstable angina: prognostic value additional to the clinical characteristics and the admission electrocardiogram. Heart 1996 75:222-28.	
	43.	Patent assignment details obtained 11/20/2009 from USPTO for Application No. 09/835,298.	
	44.	RABBANI, Editorials. Acute coronary syndromes-Beyond Myocyte necrosis. N. Engl. J. Med. 2001; 345:1057-59.	
	45.	Response dated 10/06/2010 to the summons by Patentee regarding opposition against EP1311701.	
	46.	Response dated 12/02/2010 in preparation of the oral proceedings by Patentee regarding opposition against EP1311701.	
	47.	Response dated 12/11/2009 to Opposition filed on 04/22/2009 against EP1311701 by Bio-Rad Pasteur.	
	48.	RICHARDS, et al. Plasma N-Terminal Pro-Brain Natriuretic Peptide and Adrenomedullin; New Neurohormonal Predictors of Left Ventricular Function and Prognosis After Myocardial Infarction, 1998 May 19; 97:1921-1929.	
	49.	RICHARDS, et al. Radio-immunoassay for plasma alpha human atrial natriuretic peptide: a comparison of direct and pre-extracted methods. J Hypertens. 1987 Apr;5(2):227-36.	
	50.	Rogers. The clinical spectrum of acute coronary syndromes. JA0A.Vo1100;No.11, November 2000;S1-S7.	
	51.	SABATINE et al. Multimarker Approach to Risk Stratification In Non-ST Elevation Acute Coronary Syndromes, Circulation, 2002 April 16; 105:1760-63.	
	52.	SEFERIAN, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem. 2007 May;53(5):866-73. Epub 2007 Mar 23.	
	53.	SILVER et al. BNP Consensus Panel 2004: A Clinical Approach for the Diagnostic, Prognostic, Screening, Treatment Monitoring, and Therapeutic Roles of Natriuretic Peptides in Cardiovascular Disease. CHF. 2004; 10(5 Suppl. 3):1-30.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/645,874
				Filing Date	August 20, 2003
				First Named Inventor	Kenneth F. Buechler
				Art Unit	1641
Examiner Name	Ann Y. Lam				
Sheet	5	of	5	Attorney Docket Number	36671-744.502

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	54.	Stevenson, et al. Assessment of Holter ST monitoring for risk stratification in patients with acute myocardial infarction treated by thrombolysis. Br Heart J.1993;70:233-240.	
	55.	Summons dated 04/19/2010 with opposition summary regarding opposition against EP1311701.	
	56.	SUNDSFJORD et al. Identification and Plasma Concentrations of the N-Terminal Fragment of Proatrial Natriuretic Factor In Man, J Clin Endocrinol Metab, 1988 March; 66:3:605-610.	
	57.	Swedberg, et al. Effect of the early administration of enalapril on mortality in patients with acute myocardial infarction. NEJM. 1992;327:678-84.	
	58.	TALWAR at al. Plasma N-terminal Pro-Brain Natriuretic Peptide and Cardiotrophin 1 are raised in Unstable Angina. Heart, 2000; 84:421-424.	
	59.	WU, et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem. 2004 May;50(5):867-73. Epub 2004 Mar 9.	
	60.	YANDLE, et al. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab. 1993 Apr;76(4):832-8.	
	61.	YASUE et al. Localization and Mechanism of Secretion of B-Type Natriuretic Peptide in Comparison with Those of A-Type Natriuretic Peptide in Normal Subjects and Patients with Heart Failure. Circulation. 1994 July; 90:1:195-203.	
	62.	Zaacks, et al. Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications? JACC vol133 no1, January 1999:107-18.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.